<DOC>
	<DOCNO>NCT01168479</DOCNO>
	<brief_summary>Rationale : Dose escalation external-beam irradiation proven benefit outcome local prostate cancer . Randomized trial perform dos 78 Gy 2 Gy fraction . Nevertheless , five-year biochemical relapse rate still approximately 35 % high-dose arm . Therefore dose escalation seem require . A feasibility study appr . 85 Gy entire prostate already perform show acceptable toxicity combine adequate position verification . Higher dos entire prostate expect increase severe toxicity . As local recurrence occur site primary macroscopic tumour area next step increase dose ablative boost macroscopic tumour alone , electively irradiate rest prostate current gold standard dose . Feasibility approach show ablative dose 95 Gy macroscopic tumour within prostate .</brief_summary>
	<brief_title>FLAME : Investigate Benefit Focal Lesion Ablative Microboost Prostate Cancer</brief_title>
	<detailed_description>Objective : - Primary study objective : To demonstrate superiority ablative microboost dose schedule regard 5-year biochemical evidence disease rate compare current standard care . - Secondary study objective : Establish compare rate treatment-related toxicity , quality life disease-free survival . Study design : Single blind prospective randomize controlled phase III trial . Study population : Patients intermediate high risk adenocarcinoma prostate . Intermediate high risk define accord Ash et al . 2000 criterion : - One ( intermediate-risk ) ( high-risk ) factor : T2 , Gleasonscore=7 , iPSA 10-20 ng/mL - One ( high-risk ) factor : T3 , Gleasonscore &gt; 7 , iPSA &gt; 20 ng/mL Intervention : The standard arm receive current gold standard , namely 77Gy prostate 35 fraction 2.2 Gy , 5 time per week . In experimental arm patient receive addition current gold standard 77 Gy prostate integrate boost macroscopically visible tumour reach total dose 95 Gy 35 fraction 2.7 Gy , 5 time per week . Main study endpoint : To decrease five-year biochemical relapse rate least 10 % . Nature extent burden risk associate participation , benefit group relatedness : Patients fill quality life questionnaire radiotherapy treatment . The risk associate increase dose macroscopic tumour increase toxicity reduction quality life .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Prostate cancer patient schedule external beam radiotherapy use IMRT fiducial markerbased position verification Intermediate high risk prostate cancer , define Ash et al . 2000 , namely : One factor : T2 , Gleasonscore &gt; 7 , iPSA &gt; 10 ng/mL WHO score 02 Low risk prostate cancer , define Ash et al . 2000 World Heath Organisation ( WHO ) score &gt; 2 International Prostate Symptom Score ( IPSS ) &gt; 20 If patient related reason MRI perform If anticoagulation stop temporarily regard implant fiducial marker Previous prostatectomy ( except Trans Urethral Prostatectomy ( TURP ) ) TURP within 3 month start treatment Previous pelvic irradiation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>external beam radiotherapy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>dose painting</keyword>
	<keyword>95Gy 35 fraction</keyword>
	<keyword>MRI</keyword>
	<keyword>FLAME</keyword>
</DOC>